[Clinical therapeutic effect of adoptive immunotherapy using IL-2-cultured autologous lymphocytes].
Our method of adoptive immunotherapy (AIT) using autologous IL-2-cultured lymphocytes differs from so-called LAK therapy in several points. We (1) obtain cultured lymphocytes from effusion lymphocytes (EL) or regional lymph-node lymphocytes (RLNL), when possible, rather than peripheral blood lymphocytes (PBL), (2) use crude IL-2 to induce T cell proliferation and to maintain killer activity, (3) use sonicated autologous tumor extract as antigen (Ag) to stimulate proliferation of cytotoxic T cells, and (4) pretreat the patients with local administration of OK-432 before AIT to induce effector cells that act synergistically with transferred killer cells. Surface marker analysis showed that OKT3, IL-2 receptor, Leu 2+15- cells were elevated while Leu 11a and Leu 3+8+ cells were decreased. Culture of RLNL augmented the expression of Leu 3+8- marker. Both of PBL and RLNL responded to Ag, and their auto-tumor killing activities were augmented in about half of the patients while rarely decrease by the addition of Ag. Response rates of patients with pleural effusion due to breast cancer and those with liver metastasis of breast cancer were 94% and 60%, respectively. Moreover, the survival was prolonged in the treated patients with pleural effusion or gastric cancer patients with peritoneal dissemination.
Kan
N
N
First Department of Surgery, Faculty of Medicine, Kyoto University, Japan.
Okino
T
T
Nakanishi
M
M
Satou
K
K
Mise
K
K
Ohgaki
K
K
Hori
T
T
Kodama
H
H
Tobe
T
T
D002478:Cells, Cultured; D005069:Evaluation Studies as Topic; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000639:trends; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D009369:Neoplasms / Q000628:therapy*; D010844:Picibanil / Q000627:therapeutic use
D007376:Interleukin-2; D010844:Picibanil